Effect of TMS on Neuropathic Pain for Patients With Sci

Ankara Etlik City Hospital39 enrolled

Overview

The aim of this study is to evaluate the efficacy of rTMS targeting the anterior cingulate cortex, another stimulation site that may be effective in the treatment of neuropathic pain, and to compare it with motor cortex stimulation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Spinal Cord Injury Neuropathic Pain

Interventions

active TMSDEVICE

Patients in the active or sham primary motor cortex rTMS group will receive active or sham rTMS at 5 Hz targeting the M1 area of the lower extremity motor area under medical supervision for a total of 10 sessions over 2 weeks. Patients in the active anterior cingulate cortex rTMS group will also receive active 5 Hz rTMS targeting the anterior cingulate cortex for a total of 10 sessions over 2 weeks under medical supervision.

sham TMSDEVICE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients for whom at least 12 months have passed since the date of the event 2. Patients who meet the International Pain Working Group's criteria for central neuropathic pain below the level of the lesion and who have had pain for at least 6 months 3. Patients aged 18-65 4. Pain not attributable to other causes such as rheumatological diseases or diabetes 5. Patients with VAS \> 4 despite maximum dose of pharmacological agents (anticonvulsants, antidepressants, narcotics), exercise and physical therapy agents, taking into account renal function tests and other comorbidities Exclusion Criteria: 1. History of epilepsy 2. Metallic implant in the scalp 3. Cochlear implant 4. Spinal cord stimulator 5. Pacemaker 6. Presence of psychiatric illness 7. Pregnancy

Locations (2)

Ankara Etlik City Hospital

Ankara, Yenimahalle, Turkey (Türkiye)

RECRUITING

Gaziler Physical Therapy and Rehabilitation Training and Research Hospital

Ankara, Çankaya, Turkey (Türkiye)

RECRUITING

Outcomes

Primary Outcomes

visual analog scale

The assessment of pain using a 10 cm visual analogue scale (VAS), separately for daytime and night-time. The assessment will be conducted on a scale of "0 = no pain" to "10 = the most severe pain imaginable".

Time frame: first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment

Secondary Outcomes

neuropathic pain scale

Time frame: first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment

Beck Depression Scale

Time frame: first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment

5-point Likert scale

It is a 5-point Likert scale to be used for assessing patient satisfaction.

Time frame: first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment

Central Contacts

Ayşe Naz Kalem Özgen, specialist

CONTACT

+90 0312 797 00 00 kalemnaz@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.